MHRA (UK)
OTHER
UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
Published: 7/7/2026Detected: 6/30/2026
Summary preview
Triggers a MHRA defect notification for a gabapentin oral solution due to customer-reported particles observed in some bottles, indicating a potential quality defect and consumer safety risk.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountneurology
manufacturing
quality
safety
labeling
#MHRA
#defect notification
#Class 4
#gabapentin
#oral solution
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/4010/1/2026
- Field Safety Notices: 21 to 25 September 20269/29/2026
- MHRA Safety Roundup: September 20269/29/2026
- Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/399/23/2026
- Field Safety Notices: 14 to 18 September 20269/23/2026